A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardiogenic Shock Initiative support the recommendation that placing Impella 2.5 or Impella CP pre-PCI improves outcomes.
Category: Cardiogenic Shock
Use this FDA-approved checklist to guide treatment decisions and determine if the Impella RP is right for your patients. IMP-574
Adoption of best practices improves survival for patients with Acute Myocardial Infarction and Cardiogenic Shock (AMICS) supported with Impella.
The Impella 5.0 is approved for use in cardiogenic shock, and is proven to unload the left ventricle and support the systemic circulation.
For patients in post cardiotomy cardiogenic shock (PCCS), the Impella LD can assist in the efforts to successfully unload the left ventricle and separate from bypass while offering full systemic circulatory support.
The Impella RP is the only FDA approved support device for the treatment of right heart failure.
The use of standardized protocols has been associated with improvement in outcomes for people in cardiogenic shock. Such protocols enable clinicians to quickly assess a situation and rapidly decide on next steps. These protocols present Abiomed’s cardiogenic shock guidelines and include best practices to identify, stabilize, revascularize, and reassess high-risk cardiogenic shock patients. Inserting mechanical … Continue reading “Abiomed’s Cardiogenic Shock Guidelines”
Impella 2.5®, Impella CP®, Impella 5.0®, and Impella LD® heart pumps are now FDA indicated to provide treatment of ongoing cardiogenic shock. In this setting, the Impella® heart pumps have the ability to stabilize the patient’s hemodynamics, unload the left ventricle, perfuse the end organs, and allow for recovery of the native heart.